6,6-dimethyl-1,4-diazepan-5-one | 1191544-98-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酰胺类
• 英文名称: 6,6-dimethyl-1,4-diazepan-5-one
• CAS: 1191544-98-5
• 化学式: C₇H₁₄N₂O
• mdl: MFCD19227126
• 分子量: 142.201
• InChiKey: PXFNCGVCQOBSLV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  6,6-dimethyl-1-[(2-nitrophenyl)sulfonyl]-1,4-diazepan-5-one 在 potassium carbonate 、 4-甲苯硫酚 作用下， 以 乙腈 为溶剂， 反应 3.0h， 生成 6,6-dimethyl-1,4-diazepan-5-one
  参考文献：
  名称：

  EP1803710

  摘要：

  公开号：

文献信息

• Urea inhibitors of MAP kinases
  申请人：Michelotti Luis Enrique

  公开号：US20060167247A1

  公开（公告）日：2006-07-27

  The present invention is directed to a compound having the formula wherein R 1 , R 2 , G, and Q are defined herein. The compounds of the present invention are useful as inhibitors of protein kinases such as MAP kinases, in particular p38 kinases. The present invention is also directed to compositions comprising a compound according to the above formula. The compounds and compositions described herein are useful for treating and preventing an inflammatory condition or disease. The present invention is also directed to a method of treating or preventing a protein kinase-mediated condition.

  本发明涉及一种化合物，其具有以下式子：其中R1、R2、G和Q在此处定义。本发明的化合物可用作蛋白激酶的抑制剂，例如MAP激酶，特别是p38激酶。本发明还涉及包含上述式子化合物的组合物。本发明所描述的化合物和组合物可用于治疗和预防炎症状况或疾病。本发明还涉及一种治疗或预防蛋白激酶介导病症的方法。
• Pyrimidine Derivative Condensed with a Non-Aromatic Ring
  申请人：Yonetoku Yasuhiro

  公开号：US20080070896A1

  公开（公告）日：2008-03-20

  There are provided new pyrimidine derivatives condensed with a non-aromatic ring selected from dihydrothiophene, dihydrofuran, cycloalkane moiety, and the like or pharmaceutically acceptable salts thereof; and a pharmaceutical composition comprising said compound as an active ingredient. These compounds exhibit excellent promoting activity on insulin secretion and activity against hyperglycemia. Hence, the pharmaceutical compositions comprising such compounds as active ingredients, based on these actions, are useful for treating and/or preventing insulin-dependent diabetes (type 1 diabetes), non-insulin-dependent diabetes (type 2 diabetes), insulin-resistant diseases, obesity, and the like.

  提供了一些新的嘧啶衍生物，其与二氢噻吩、二氢呋喃、环烷基等非芳香环结构缩合，或其药学上可接受的盐缩合；以及一种含有该化合物作为活性成分的制药组合物。这些化合物表现出对胰岛素分泌的促进活性和对高血糖的活性。因此，基于这些作用，包含这些化合物作为活性成分的制药组合物可用于治疗和/或预防胰岛素依赖性糖尿病（1型糖尿病）、非胰岛素依赖性糖尿病（2型糖尿病）、胰岛素抵抗性疾病、肥胖症等。
• PYRIMIDINE DERIVATIVE CONDENSED WITH NON-AROMATIC RING
  申请人：Astellas Pharma Inc.

  公开号：EP1803710A1

  公开（公告）日：2007-07-04

  There are provided new pyrimidine derivatives condensed with a non-aromatic ring selected from dihydrothiophene, dihydrofuran, cycloalkane moiety, and the like or pharmaceutically acceptable salts thereof; and a pharmaceutical composition comprising said compound as an active ingredient. These compounds exhibit excellent promoting activity on insulin secretion and activity against hyperglycemia. Hence, the pharmaceutical compositions comprising such compounds as active ingredients, based on these actions, are useful for treating and/or preventing insulin-dependent diabetes (type 1 diabetes), non-insulin-dependent diabetes (type 2 diabetes), insulin-resistant diseases, obesity, and the like.

  提供了与选自二氢噻吩、二氢呋喃、环烷基等的非芳香环缩合的新嘧啶衍生物或其药学上可接受的盐；以及包含上述化合物作为活性成分的药物组合物。这些化合物对胰岛素分泌和高血糖具有良好的促进作用。因此，基于这些作用，包含此类化合物作为活性成分的药物组合物可用于治疗和/或预防胰岛素依赖型糖尿病（1 型糖尿病）、非胰岛素依赖型糖尿病（2 型糖尿病）、胰岛素抵抗性疾病、肥胖症等。
• UREA INHIBITORS OF MAP KINASES
  申请人：Locus Pharmaceuticals, Inc.

  公开号：EP1828169A2

  公开（公告）日：2007-09-05
• US7741479B2
  申请人：——

  公开号：US7741479B2

  公开（公告）日：2010-06-22